A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
← catalyst calendarNCT05076175 · readout in 2,154 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
120estimated
Sites
90
Countries
Australia, Belgium, Canada +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-30 | actual | When the study began enrolling |
| Primary completion | 2032-07-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-07-12 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colitis, Ulcerative
Intervention
- Drug: Ozanimod — also filed as RPC1063
Primary outcome
what the primary-completion date above is the date OFProportion of participants who achieve clinical remission
measured At Week 52
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed